TScan Therapeutics Enters Securities Purchase Agreement With Lynx1 Capital, Investment Fund Advised By Lynx1 For Sale Of $30M Of Pre-funded Warrants To Buy Up To Aggregate Of 7.50M Shares Of Voting Common Stock At $4.00 Per Pre-funded Warrant
Author: Benzinga Newsdesk | December 26, 2024 08:03am